News

Pharmabiz16h
PCI asks State Councils to submit consolidated data of pharmacists for HPR
PCI asks State Councils to submit consolidated data of pharmacists for HPR: Our Bureau, New Delhi Saturday, July 19, 2025, 08 ...
Pharmabiz6h
Prima Mente launches Pleiades, a human epigenome foundation model with applications for Alzheimer’s disease
Prima Mente launches Pleiades, a human epigenome foundation model with applications for Alzheimer’s disease: London Saturday, July 19, 2025, 18:00 Hrs [IST] San Francisco and Lo ...
Pharmabiz7h
Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation
Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation: Palo Alto, California Saturday, July 19, 2025, 16:30 Hrs [IST] ...
Pharmabiz7h
Repare Therapeutics signs exclusive global licensing agreement with Debiopharm International for lunresertib
Repare Therapeutics signs exclusive global licensing agreement with Debiopharm International for lunresertib: Cambridge, Massachusetts Saturday, July 19, 2025, 17:00 Hrs [IST] Rep ...
Pharmabiz10h
Jaya Biosciences receives patent notices of allowance in Singapore, Japan & China to treat neurological diseases including Alzheimer’s disease
South San Francisco, California Saturday, July 19, 2025, 14:00 Hrs [IST] ...
Pharmabiz8h
Nanochon gets Health Canada approval for first in human investigation to assess safety and performance of its Chondrograft system
Nanochon gets Health Canada approval for first in human investigation to assess safety and performance of its Chondrograft system: Washington Saturday, July 19, 2025, 16:00 Hrs [I ...
Pharmabiz11h
US FDA accepts resubmitted NDA of Aldeyra Therapeutics for review of topical ocular reproxalap to treat dry eye disease
US FDA accepts resubmitted NDA of Aldeyra Therapeutics for review of topical ocular reproxalap to treat dry eye disease: Lexington, Massachusetts Saturday, July 19, 2025, 13:00 Hr ...
Pharmabiz8h
Synendos Therapeutics appoints Dr. George Garibaldi as CMO to enhance phase 2 clinical development of its lead drug asset SYT-510
Synendos Therapeutics appoints Dr. George Garibaldi as CMO to enhance phase 2 clinical development of its lead drug asset SYT-510: Basel, Switzerland Saturday, July 19, 2025, 15:3 ...
Pharmabiz9h
Rocket Pharma receives US FDA regenerative medicine advanced therapy designation for RP-A601 gene therapy
Rocket Pharma receives US FDA regenerative medicine advanced therapy designation for RP-A601 gene therapy: Cranbury, New Jersey Saturday, July 19, 2025, 15:00 Hrs [IST] Rocket Pha ...
Pharmabiz12h
SK bioscience seeks Korean regulatory approval to initiate phase 1/2 trial of adjuvanted influenza vaccine candidate, NBP607B
Seongnam, South Korea Saturday, July 19, 2025, 12:00 Hrs [IST] ...
Pharmabiz15h
Sanofi completes acquisition of Blueprint Medicines
Sanofi, an R&D driven, AI-powered biopharma company, announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a ...
Pharmabiz16h
Applications invited for Pharmexcil Awards for outstanding export performance in FY 2023–24
Applications invited for Pharmexcil Awards for outstanding export performance in FY 2023–24: Shardul Nautiyal, Mumbai Saturday, July 19, 2025, 08:00 Hrs [IST] The Pharmaceutical ...